The damage caused by the formation of chronic lymphocytic leukemia lesions is different for each patient, and changes in the effectiveness of treatment will vary from person to person. What the average life expectancy is will also vary from person to person, and there is no certain regularity.
For patients with chronic lymphocytic leukemia, the course of the disease varies. Some patients will survive for six months and some for more than ten years. Most patients will die from severe anemia, bleeding and infection caused by bone marrow failure. Each patient’s ability to receive timely and targeted treatment can have a significant impact on mortality and survival time in later stages of the disease.
Chronic lymphocytic leukemia is a malignant neoplastic lesion of primary hematopoietic tissues that involves varying degrees of damage to blood, bone marrow, and lymphocyte tissues after repeated effects and injuries to one’s own hematopoietic tissues. After the aggravation of autohematopoietic lesions, if it cannot be treated in time, the survival period of patients is shorter.
In summary, in the process of chronic lymphocytic leukemia, each patient’s body damage degree is different, the late treatment effect of the changes will directly affect the survival time, and there is no regularity, life expectancy more or less is not accurate is time. If diagnosed with chronic leukemia, it is recommended that patients seek treatment as early as possible to prolong survival.